Neurocrine Biosciences (NBIX) : Nexthera Capital Lp scooped up 15,000 additional shares in Neurocrine Biosciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 42,000 shares of Neurocrine Biosciences which is valued at $1.8 Million.Neurocrine Biosciences makes up approximately 2.00% of Nexthera Capital Lp’s portfolio.
Other Hedge Funds, Including , Brown Advisory Inc boosted its stake in NBIX in the latest quarter, The investment management firm added 81,033 additional shares and now holds a total of 309,489 shares of Neurocrine Biosciences which is valued at $13.5 Million. Neurocrine Biosciences makes up approx 0.05% of Brown Advisory Inc’s portfolio.Callan Capital boosted its stake in NBIX in the latest quarter, The investment management firm added 7,000 additional shares and now holds a total of 22,000 shares of Neurocrine Biosciences which is valued at $960,300. Neurocrine Biosciences makes up approx 0.41% of Callan Capital’s portfolio.Pioneer Investment Management Inc boosted its stake in NBIX in the latest quarter, The investment management firm added 3,553 additional shares and now holds a total of 193,026 shares of Neurocrine Biosciences which is valued at $8.4 Million. Neurocrine Biosciences makes up approx 0.03% of Pioneer Investment Management Inc’s portfolio. First Trust Advisors Lp added NBIX to its portfolio by purchasing 638,287 company shares during the most recent quarter which is valued at $27.9 Million. Neurocrine Biosciences makes up approx 0.09% of First Trust Advisors Lp’s portfolio. Cqs Cayman Lp sold out all of its stake in NBIX during the most recent quarter. The investment firm sold 90,000 shares of NBIX which is valued $3.9 Million.
Neurocrine Biosciences closed down -2.21 points or -4.53% at $46.56 with 11,42,981 shares getting traded on Wednesday. Post opening the session at $49.06, the shares hit an intraday low of $46.01 and an intraday high of $49.44 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Neurocrine Biosciences reported $-0.22 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.29. The company had revenue of $15.00 million for the quarter, compared to analysts expectations of $15.43 million. The company’s revenue was down -24.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.01 EPS.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.